Treatment awaited by cancer patients: 'The exact date cannot be given'

24ur (POP TV)IndependentCenterFactual 90Objective 853 days ago

The article discusses the development of CAR-T cell therapy in Slovenia, a personalized immunotherapy used to treat certain aggressive blood cancers. While the treatment has been approved in the U.S. and Europe since 2017 and 2018 respectively, Slovenia's academic CAR-T center has yet to receive final regulatory approval five years after the project began. The article highlights the efforts of the L&L patient association, which led a donation campaign in 2021 that raised €850,000 to purchase two critical pieces of equipment for the center. Despite this progress, the center still awaits final authorization from the Slovenian Agency for Medicinal Products and Medical Devices (JAZMP), raising concerns among patients, donors, and medical professionals about delays and their impact on cancer care.

Bias read (Center): The article provides factual information about the status of CAR-T therapy in Slovenia, including the timeline of approvals abroad, the local development process, and the role of the L&L patient association. It does not exhibit overtly biased language, one-sided sourcing, or editorializing that tilт

Why these scores (Factual 90 · Objective 85): The article provides accurate information about CAR-T therapy, including its mechanism, current applications, and regulatory status. It references the FDA approval of Kymriah in 2017 and EU approval in 2018, aligning with cross-source consensus. The mention of the Slovenian academic CAR-T center wai

24ur (POP TV)IndependentCenter10 hr. ago

The article discusses delays in the approval process for CAR-T therapy for cancer patients in Slovenia, focusing on the role of the Slovenian Agency for Medicinal Products (JAZMP). It highlights concerns raised by the Association of Patients with Lymphoma and Leukemia regarding the administrative burden and the importance of ensuring quality, safety, and proper oversight of advanced therapies. The article explains that CAR-T is classified as a gene therapy and requires specific regulatory approvals. It outlines the timeline of submissions made by two institutions—University of Ljubljana and the Institute of Microbiology and Immunology—and notes that both were requested to complete their documentation. However, recent changes in regulations and the establishment of a new public agency for healthcare quality have added further complexity to the approval process.

Bias read (Center): The article presents information about the regulatory process for CAR-T therapy without overtly favoring any political side. While it mentions the challenges faced by stakeholders and the evolving regulatory landscape, it does not take a clear ideological stance. The focus remains on factual updates